The most significant transaction on today’s list comes in a Form 4 filing by Matrix Capital Management.
The hedge fund reported the acquisition of 4,760,000 shares, equivalent to $107.8 million, in the small-cap biotech company Zentalis Pharmaceuticals, Inc $ZNTL.